Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase

Basic and Clinical Pharmacology and Toxicology

Volumn 100, Issue 6, 2007, Pages 392-397

  Gueguen, Yann ^a,b   Ferrari, Luc ^a   Souidi, Maâmar ^b   Batt, Anne Marie ^a   Lutton, Claude ^c   Siest, Gérard ^a   Visvikis, Sophie ^a  

^a INSERM   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; RAPAMYCIN; STEROL 27 HYDROXYLASE;

ARTICLE; CELL STRAIN HEPG2; CHOLESTEROL HOMEOSTASIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MITOCHONDRION; PRIORITY JOURNAL; UPREGULATION;

CELL LINE, TUMOR; CHOLESTEROL; CYCLOSPORINE; CYTOCHROME P-450 CYP27A1; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; IMMUNOSUPPRESSIVE AGENTS; MITOCHONDRIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIROLIMUS;

EID: 34249074769     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00066.x     Document Type: Article

References (38)

1. Kay JE, Benzie CR, Goodier MR, Wick CJ, Doe SE. Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506. Immunology 1989 67 : 473 7.
2. Gueguen Y, Ferrari L, Batt AM. [Dyslipidaemia and its management after immunosuppressive treatment]. Therapie 2004 59 : 463 9.
3. Brattstrom C, Wilczek H, Tyden G, Bottiger Y, Sawe J, Groth CG. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998 65 : 1272 4.
4. Paul LC. Adverse effects of immunosuppressive drugs on long-term graft outcome. Transplant Proc 1998 30 : 4001 4.
5. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998 66 : 1040 6.
6. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000 22 Suppl B : B101 21.
7. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996 49 : 209 16.
8. Javitt NB. Bile acid synthesis from cholesterol: regulatory and auxiliary pathways. FASEB J 1994 8 : 1308 11.
9. Esterman AL, Baum H, Javitt NB, Darlington GJ. 26-hydroxycholesterol: regulation of hydroxymethylglutaryl-CoA reductase activity in Chinese hamster ovary cell culture. J Lipid Res 1983 24 : 1304 9.
10. Tamasawa N, Hayakari M, Murakami H, Matsui J, Suda T. Reduction of oxysterol levels up-regulates HMG-CoA reductase activity in rat liver. Atherosclerosis 1997 131 : 237 42.
11. Axelson M, Larsson O. Low density lipoprotein (LDL) cholesterol is converted to 27-hydroxycholesterol in human fibroblasts. Evidence that 27-hydroxycholesterol can be an important intracellular mediator between LDL and the suppression of cholesterol production. J Biol Chem 1995 270 : 15102 10.
12. Babiker A, Andersson O, Lund E et al. Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport. J Biol Chem 1997 272 : 26253 61.
13. Princen HM, Meijer P, Wolthers BG, Vonk RJ, Kuipers F. Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis. Biochem J 1991 275 (P t 2 501 5.
14. Winegar DA, Salisbury JA, Sundseth SS, Hawke RL. Effects of cyclosporin on cholesterol 27-hydroxylation and LDL receptor activity in HepG2 cells. J Lipid Res 1996 37 : 179 91.
15. Souidi M, Parquet M, Ferezou J, Lutton C. Modulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase activities by steroids and physiological conditions in hamster. Life Sci 1999 64 : 1585 93.
16. Oftebro H, Bjorkhem I, Skrede S, Schreiner A, Pederson JI. Cerebrotendinous xanthomatosis: a defect in mitochondrial 26-hydroxylation required for normal biosynthesis of cholic acid. J Clin Invest 1980 65 : 1418 30.
17. Rennert H, Fischer RT, Alvarez JG, Trzaskos JM, Strauss JF, 3rd. Generation of regulatory oxysterols: 26-hydroxylation of cholesterol by ovarian mitochondria. Endocrinology 1990 127 : 738 46.
18. Bjorkhem I, Andersson O, Diczfalusy U et al. Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages. Proc Natl Acad Sci USA 1994 91 : 8592 6.
19. Vlahcevic ZR, Stravitz RT, Heuman DM, Hylemon PB, Pandak WM. Quantitative estimations of the contribution of different bile acid pathways to total bile acid synthesis in the rat. Gastroenterology 1997 113 : 1949 57.
20. Salen G, Berginer V, Shore V et al. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid. N Engl J Med 1987 316 : 1233 8.
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987 162 : 156 9.
22. Shoda J, He BF, Tanaka N et al. Increase of deoxycholate in supersaturated bile of patients with cholesterol gallstone disease and its correlation with de novo syntheses of cholesterol and bile acids in liver, gallbladder emptying, and small intestinal transit. Hepatology 1995 21 : 1291 302.
23. Andreou ER, Prokipcak RD. Analysis of human CYP7A1 mRNA decay in HepG2 cells by reverse transcription-polymerase chain reaction. Arch Biochem Biophys 1998 357 : 137 46.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951 193 : 265 75.
25. Pandak WM, Stravitz RT, Lucas V, Heuman DM, Chiang JY. Hep G2 cells: a model for studies on regulation of human cholesterol 7α-hydroxylase at the molecular level. Am J Physiol 1996 270 : G401 10.
26. Pandak WM, Schwarz C, Hylemon PB et al. Effects of CYP7A1 overexpression on cholesterol and bile acid homeostasis. Am J Physiol Gastrointest Liver Physiol 2001 281 : G878 89.
27. Dahlback-Sjoberg H, Bjorkhem I, Princen HM. Selective inhibition of mitochondrial 27-hydroxylation of bile acid intermediates and 25-hydroxylation of vitamin D3 by cyclosporin A. Biochem J 1993 293 (P t 1 203 6.
28. Segev H, Honigman A, Rosen H, Leitersdorf E. Transcriptional regulation of the human sterol 27-hydroxylase gene (CYP27) and promoter mapping. Atherosclerosis 2001 156 : 339 47.
29. Deters M, Kirchner G, Koal T, Resch K, Kaever V. Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. Dig Dis Sci 2004 49 : 30 7.
30. Deters M, Nolte K, Kirchner G, Resch K, Kaever V. Comparative study analyzing effects of sirolimus-cyclosporin and sirolimus-tacrolimus combinations on bile flow in the rat. Dig Dis Sci 2001 46 : 2120 6.
31. Kuhn B, Jacobsen W, Christians U, Benet LZ, Kollman PA. Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. J Med Chem 2001 44 : 2027 34.
32. Graham SE, Peterson JA. How similar are P450s and what can their differences teach us? Arch Biochem Biophys 1999 369 : 24 9.
33. Martin KO, Reiss AB, Lathe R, Javitt NB. 7α-hydroxylation of 27-hydroxycholesterol: biologic role in the regulation of cholesterol synthesis. J Lipid Res 1997 38 : 1053 8.
34. Wu J, Zhu YH, Patel SB. Cyclosporin-induced dyslipoproteinemia is associated with selective activation of SREBP-2. Am J Physiol 1999 277 : E1087 94.
35. Hall E, Hylemon P, Vlahcevic Z et al. Overexpression of CYP27 in hepatic and extrahepatic cells: role in the regulation of cholesterol homeostasis. Am J Physiol Gastrointest Liver Physiol 2001 281 : G293 301.
36. Crisby M, Nilsson J, Kostulas V, Bjorkhem I, Diczfalusy U. Localization of sterol 27-hydroxylase immuno-reactivity in human atherosclerotic plaques. Biochim Biophys Acta 1997 1344 : 278 85.
37. Russell DW. Oxysterol biosynthetic enzymes. Biochim Biophys Acta 2000 1529 : 126 35.
38. Diczfalusy U, Lund E, Lutjohann D, Bjorkhem I. Novel pathways for elimination of cholesterol by extrahepatic formation of side-chain oxidized oxysterols. Scand J Clin Lab Invest Suppl 1996 226 : 9 17.